Dupilumab, a monoclonal antibody against the interleukin-4 receptor, has been shown to reduce exacerbations and improve lung function in moderate-severe uncontrolled asthma and also reduce reliance on steroids. The phase 3 trials, presented at ATS 2018 and published in the New England Journal of Medicine, found the benefits were seen regardless of baseline blood eosinophil ...
New mAb halves exacerbation rates and cuts steroid reliance in severe asthma
By Mardi Chapman
29 May 2018